TODARO, MARIA
 Distribuzione geografica
Continente #
NA - Nord America 1.547
EU - Europa 855
AS - Asia 511
AF - Africa 21
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
SA - Sud America 2
Totale 2.945
Nazione #
US - Stati Uniti d'America 1.537
CN - Cina 289
DE - Germania 156
IT - Italia 140
SG - Singapore 130
SE - Svezia 106
IE - Irlanda 93
AT - Austria 79
DK - Danimarca 50
UA - Ucraina 45
FR - Francia 42
FI - Finlandia 32
GB - Regno Unito 31
IN - India 21
CH - Svizzera 14
SN - Senegal 14
BY - Bielorussia 13
VN - Vietnam 13
BE - Belgio 12
HK - Hong Kong 12
JP - Giappone 12
CA - Canada 10
ES - Italia 9
PL - Polonia 9
KR - Corea 8
RU - Federazione Russa 8
ID - Indonesia 6
NL - Olanda 6
TH - Thailandia 5
AU - Australia 4
EU - Europa 4
SA - Arabia Saudita 4
ZA - Sudafrica 4
RS - Serbia 3
TR - Turchia 3
UZ - Uzbekistan 3
CZ - Repubblica Ceca 2
PH - Filippine 2
RO - Romania 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BR - Brasile 1
CI - Costa d'Avorio 1
EG - Egitto 1
GR - Grecia 1
HU - Ungheria 1
LT - Lituania 1
NZ - Nuova Zelanda 1
TG - Togo 1
Totale 2.945
Città #
Chandler 271
Beijing 140
Santa Clara 139
Singapore 107
Ann Arbor 105
Dublin 93
Vienna 73
Ashburn 67
Dearborn 63
Torino 62
Fairfield 61
Nyköping 46
Wilmington 46
Houston 39
Woodbridge 37
Jacksonville 36
Medford 35
Redwood City 30
Columbus 27
Princeton 27
Fremont 22
Villeurbanne 21
Seattle 20
Guangzhou 19
San Mateo 17
Cambridge 16
Helsinki 16
New York 15
Shanghai 14
Brussels 12
Dong Ket 12
Pisa 12
Hefei 10
Turin 10
Hangzhou 9
Chennai 8
Norwalk 8
Oerlikon 8
Warsaw 8
Central District 7
Chengdu 7
Los Angeles 7
Nanjing 7
Falls Church 6
Jakarta 6
Linden 6
Munich 6
San Jose 6
Thening 6
Wayne 6
Boardman 5
Milan 5
Rome 5
Shenyang 5
Tokyo 5
Bologna 4
Boston 4
Erlangen 4
Philadelphia 4
Piemonte 4
Rochester 4
San Diego 4
Somerville 4
Wuhan 4
Zhengzhou 4
Balingen 3
Belgrade 3
Cape Town 3
Changsha 3
Fuzhou 3
Hamburg 3
Kunming 3
Langreo 3
Mortara 3
Nürnberg 3
Phoenix 3
Swindon 3
Toronto 3
Bengaluru 2
Birmingham 2
Camden 2
Catanzaro 2
Changchun 2
Chicago 2
Dudley 2
Falkenstein 2
Guiyang 2
Harbin 2
Hong Kong 2
Jinan 2
Noventa Vicentina 2
Ocala 2
Ottawa 2
Paris 2
Pittsburgh 2
Prague 2
Pune 2
Seoul 2
Shaoxing 2
Sydney 2
Totale 1.979
Nome #
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. 365
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 292
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma 176
The influence of tissue ischemia time on RNA integrity and patient-derived xenografts (PDX) engraftment rate in a non-small cell lung cancer (NSCLC) Biobank 173
Magic pills: new oral drugs to treat chronic lymphocytic leukemia 149
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 147
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma 142
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance 115
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 114
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 108
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE 99
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 92
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target 88
The CXCR4 downstream signaling pathways in chronic lymphocytic leukemia: a target to reverse microenvironment protection 84
TARGETING THE CXCR4 DOWNSTREAM SIGNALLING PATHWAYS TO REVERSE MICROENVIRONMENT PROTECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 81
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 79
Targeting hif-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in cll 79
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells 78
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells 75
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms 74
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 71
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 70
REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE 70
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 64
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 56
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells 49
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia 30
Totale 3.020
Categoria #
all - tutte 8.757
article - articoli 0
book - libri 0
conference - conferenze 4.867
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.624


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020347 0 0 0 0 0 68 48 37 49 65 36 44
2020/2021397 41 40 22 28 53 21 23 29 22 18 68 32
2021/2022421 24 6 12 42 26 9 35 24 11 42 117 73
2022/2023580 75 64 27 60 52 124 34 37 53 21 26 7
2023/2024242 28 46 9 8 16 44 12 18 8 14 12 27
2024/2025390 8 27 43 65 204 43 0 0 0 0 0 0
Totale 3.020